Fudan University

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1905-01-01

Employees: 1K

Market Cap: -

Website: http://www.fudan.edu.cn

Clinical Trials

Real World Study of Diagnosis and First-line Treatment Among Patients With Cancer of Unknown Primary in China

Conditions: Cancer of Unknown Primary Site

First Posted Date: 2021-07-07

Last Posted Date: 2021-07-07

Lead Sponsor: Fudan University

Target Recruit Count: 200

Registration Number: NCT04952103

Locations: 🇨🇳
Fudan University Shanghai Cencer Center, Shanghai, Shanghai, China

The Combination of Fruquintinib, Tislelizumab and Stereotactic Ablative Radiotherapy in Metastatic Colorectal Cancer(RIFLE)

Phase 2

Conditions: Metastatic Colorectal Cancer

Interventions: Radiation: Stereotactic Ablative Radiotherapy (SABR)
Drug: Fruquintinib
Drug: Tislelizumab

First Posted Date: 2021-07-01

Last Posted Date: 2021-08-27

Lead Sponsor: Fudan University

Target Recruit Count: 68

Registration Number: NCT04948034

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Single Arm Phase II Study of Fractionated Stereotatic Radiation Therapy (FSRT) for Bone Metastases in Breast Cancer

Phase 1

Recruiting

Conditions: Breast Cancer
Bone Metastases

Interventions: Radiation: Fractionated Stereotatic Radiation Therapy

First Posted Date: 2021-07-01

Last Posted Date: 2021-07-01

Lead Sponsor: Fudan University

Target Recruit Count: 120

Registration Number: NCT04947280

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Single-cell Sequencing and Establishment of Models in Neuroendocrine Neoplasm

Conditions: Neuroendocrine Neoplasm

Interventions: Procedure: Biopsy, open or laparoscopic surgery

First Posted Date: 2021-06-16

Last Posted Date: 2021-09-24

Lead Sponsor: Fudan University

Target Recruit Count: 200

Registration Number: NCT04927611

Locations: 🇨🇳
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University, Shanghai, Shanghai, China

Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS-C/D)

Phase 2

Not yet recruiting

Conditions: Breast Cancer

Interventions: Drug: capecitabine and trastuzumab
Drug: vinorelbine and trastuzumab

First Posted Date: 2021-06-10

Last Posted Date: 2021-06-10

Lead Sponsor: Fudan University

Target Recruit Count: 356

Registration Number: NCT04922008

Immunotherapy and Chemotherapy in Unresectable Recurrent Loco-regionally Advanced Nasopharyngeal Carcinoma

Phase 2

Conditions: Recurrent Nasopharyngeal Carcinoma
Unresectable Nasopharyngeal Carcinoma
Chemotherapy Effect
Immunotherapy
Stereotactic Body Radiation Therapy (SBRT)

Interventions: Drug: Tislelizumab

First Posted Date: 2021-06-10

Last Posted Date: 2022-04-04

Lead Sponsor: Fudan University

Target Recruit Count: 40

Registration Number: NCT04921995

Locations: 🇨🇳
Eye and ENT Hospital of Fudan University, Shanghai, China

CTC vs Radiography as the Evidence of Recurrence in Colorectal Cancer Patients

Phase 3

Not yet recruiting

Conditions: Colorectal Cancer
Circulating Tumor Cell

Interventions: Drug: Chemotherapy

First Posted Date: 2021-06-08

Last Posted Date: 2021-06-08

Lead Sponsor: Fudan University

Target Recruit Count: 100

Registration Number: NCT04917289

Treatment Response Prediction System of mCRC Patients Based on CTC

Not yet recruiting

Conditions: Circulating Tumor Cell
Colorectal Cancer Stage IV

Interventions: Diagnostic Test: Circulating tumor cell

First Posted Date: 2021-06-08

Last Posted Date: 2021-06-08

Lead Sponsor: Fudan University

Target Recruit Count: 100

Registration Number: NCT04917276

Tislelizumab in Combination With Eribulin for Patients With Metastatic Previously heaviLy-treAted TriplE-negative Breast Cancer：A Prospective Multiple-center Phase II Study

Phase 2

Conditions: Triple Negative Breast Cancer

Interventions: Drug: Eribulin
Drug: Tislelizumab

First Posted Date: 2021-06-04

Last Posted Date: 2021-06-04

Lead Sponsor: Fudan University

Target Recruit Count: 265

Registration Number: NCT04913571

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Preoperative Irinotecan Drug-eluting Beads for Patients With Unresectable Colorectal Liver Metastasis

Phase 3

Conditions: Colorectal Cancer
Liver Metastases

Interventions: Drug: Trans arterial chemoembolization with Irinotecan Drug-eluting Beads

First Posted Date: 2021-06-03

Last Posted Date: 2021-06-03

Lead Sponsor: Fudan University

Target Recruit Count: 80

Registration Number: NCT04912258

Locations: 🇨🇳
Zhongshan Hospital Fudan University, Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy